Cornea/External Disease News

BOSTON — Annual exams with topography are key to identifying progression in patients with keratoconus regardless of whether they have undergone cross-linking, according to a speaker here.

A 28-year-old Latino woman presented to the University of New Mexico emergency department with the complaint of acute onset left eye pain, photophobia and visual decline.

Ocular parasitosis consistently perplexes ophthalmologists due to its varied and unpredictable presentations. The elusive nature of the disease ensures it remains concealed unless actively sought out through diligent examination.

More than half of all patients treated with glaucoma medications have ocular surface disease, which predominantly manifests as dry eye disease.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses the company’s cell therapy for corneal endothelial disease.

The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

Nearly 5 months after the FDA did not approve reproxalap for dry eye, Aldeyra Therapeutics has announced a plan to resubmit a new drug application for the reactive aldehyde species modulator, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, and Julia Katsev Larson, OD, discuss the use of Miebo for dry eye disease.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement.

When children and teens present with early onset of keratoconus, we often see severe disease and rapid progression.